{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:08:30Z","timestamp":1791875310940,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ajo.2025.06.012","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:41:57Z","timestamp":1749656517000},"page":"22-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Eplerenone and Spironolactone for Chronic Central Serous Chorioretinopathy: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"278","author":[{"given":"Ryan S","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Benour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko M","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0465-6472","authenticated-orcid":false,"given":"Rajeev H","family":"Muni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sarraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SriniVas R","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha P","family":"Kohly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajo.2025.06.012_bib0001","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","article-title":"Central serous chorioretinopathy","volume":"86","author":"Wang","year":"2008","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.06.012_bib0002","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","article-title":"Central serous chorioretinopathy: update on pathophysiology and treatment","volume":"58","author":"Nicholson","year":"2013","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.06.012_bib0003","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","article-title":"The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002","volume":"115","author":"Kitzmann","year":"2008","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2025.06.012_bib0004","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1442-9071.2012.02848.x","article-title":"Central serous chorioretinopathy: a review of epidemiology and pathophysiology","volume":"41","author":"Liew","year":"2013","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2025.06.012_bib0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1001\/archopht.1996.01100130681007","article-title":"The long-term outcome of central serous chorioretinopathy","volume":"114","author":"Yap","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.06.012_bib0006","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1442-9071.2005.01027.x","article-title":"Long-term macular function in eyes with central serous chorioretinopathy","volume":"33","author":"Baran","year":"2005","journal-title":"Clin Exp Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2025.06.012_bib0007","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ophtha.2008.04.014","article-title":"Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial","volume":"115","author":"Chan","year":"2008","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2025.06.012_bib0008","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","article-title":"Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic Central serous chorioretinopathy: the PLACE trial","volume":"125","author":"van Dijk","year":"2018","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2025.06.012_bib0009","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11096-017-0460-4","article-title":"Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis","volume":"39","author":"Ji","year":"2017","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"10.1016\/j.ajo.2025.06.012_bib0010","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10792-016-0377-2","article-title":"Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy","volume":"37","author":"Pichi","year":"2017","journal-title":"Int Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.06.012_bib0011","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0161-6420(02)01975-9","article-title":"Endocrine abnormalities in patients with central serous chorioretinopathy","volume":"110","author":"Haimovici","year":"2003","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2025.06.012_bib0012","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41433-021-01808-3","article-title":"Pathophysiology of central serous chorioretinopathy: a literature review with quality assessment","volume":"36","author":"Kanda","year":"2022","journal-title":"Eye (L)"},{"issue":"10","key":"10.1016\/j.ajo.2025.06.012_bib0013","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1097\/IAE.0b013e318297a07a","article-title":"Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study","volume":"33","author":"Bousquet","year":"2013","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.ajo.2025.06.012_bib0014","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1111\/aos.12392","article-title":"The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy","volume":"92","author":"Breukink","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"10220","key":"10.1016\/j.ajo.2025.06.012_bib0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","article-title":"Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial","volume":"395","author":"Lotery","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ajo.2025.06.012_bib0016","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1475-1313.2010.00766.x","article-title":"Transforming scales of measurement of visual acuity at the group level","volume":"30","author":"Khoshnood","year":"2010","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.ajo.2025.06.012_bib0017","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ajo.2025.06.012_bib0018","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ajo.2025.06.012_bib0019","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.ajo.2025.06.012_bib0020","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajo.2025.06.012_bib0021","first-page":"241","article-title":"Analysing data and undertaking meta-analyses","author":"Deeks","year":"2019","journal-title":"Cochrane Handb Syst Rev Interv"},{"key":"10.1016\/j.ajo.2025.06.012_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.675295","article-title":"Routine clinical practice treatment outcomes of eplerenone in acute and chronic Central serous chorioretinopathy","volume":"12","author":"Fasler","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.ajo.2025.06.012_bib0023","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000444058","article-title":"Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis","volume":"56","author":"Kapoor","year":"2016","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.ajo.2025.06.012_bib0024","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.2147\/OPTH.S260998","article-title":"Oral spironolactone versus conservative treatment for non-resolving Central serous chorioretinopathy in real-life practice","volume":"14","author":"Sinawat","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2025.06.012_bib0025","article-title":"OCT-A in chronic central serous chorioretinopathy treated with oral eplerenone and half-fluence photodynamic therapy: a comparative study","author":"Clemente","year":"2022","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2025.06.012_bib0026","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1097\/IAE.0000000000002507","article-title":"Comparison of visual\/anatomical outcomes and recurrence rate between oral spironolactone and photodynamic therapy for nonresolving Central serous chorioretinopathy","volume":"40","author":"Kim","year":"2020","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2025.06.012_bib0027","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/IAE.0000000000001913","article-title":"Comparison of short-term efficacy between oral spironolactone treatment and photodynamic therapy for the treatment of nonresolving Central serous chorioretinopathy","volume":"39","author":"Lee","year":"2019","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.ajo.2025.06.012_bib0028","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1177\/1120672121991053","article-title":"Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: a comparative study","volume":"31","author":"Manayath","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.06.012_bib0029","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1038\/s41598-022-08764-2","article-title":"Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy","volume":"12","author":"Toto","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ajo.2025.06.012_bib0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/08820538.2020.1809682","article-title":"Subthreshold micro-pulse yellow laser and eplerenone drug therapy in chronic Central serous chorio-retinopathy patients: a comparative study","volume":"35","author":"Vignesh","year":"2020","journal-title":"Semin Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.06.012_bib0031","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/IAE.0000000000001649","article-title":"A randomized double-blind placebo-control pilot study of eplerenone for the treatment of Central serous chorioretinopathy (ECSELSIOR)","volume":"38","author":"Rahimy","year":"2018","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.ajo.2025.06.012_bib0032","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1111\/aos.13491","article-title":"Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study","volume":"95","author":"Schwartz","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ajo.2025.06.012_bib0033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ajo.2021.06.020","article-title":"Half-dose photodynamic therapy versus eplerenone in chronic Central serous chorioretinopathy (SPECTRA): a randomized controlled trial","volume":"233","author":"van Rijssen","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.06.012_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101236","article-title":"Central serous chorioretinopathy: an evidence-based treatment guideline","volume":"101","author":"Feenstra","year":"2024","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"10.1016\/j.ajo.2025.06.012_bib0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40942-022-00385-1","article-title":"Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses","volume":"8","author":"Felipe","year":"2022","journal-title":"Int J Retina Vitr"},{"issue":"1","key":"10.1016\/j.ajo.2025.06.012_bib0036","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41467-018-08125-6","article-title":"Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration","volume":"10","author":"Zhao","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajo.2025.06.012_bib0037","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40942-018-0137-8","article-title":"Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature","volume":"4","author":"Chatziralli","year":"2018","journal-title":"Int J Retina Vitr"},{"issue":"4","key":"10.1016\/j.ajo.2025.06.012_bib0038","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1177\/1120672120952648","article-title":"Eplerenone for treatment of chronic central serous chorioretinopathy","volume":"31","author":"Fraenkel","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2025.06.012_bib0039","article-title":"Eplerenone treatment in chronic Central serous chorioretinopathy","volume":"13","author":"Iqbal","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.ajo.2025.06.012_bib0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.5.2.2","article-title":"Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving Central serous chorioretinopathy with chronic epitheliopathy","volume":"5","author":"Daruich","year":"2016","journal-title":"Transl Vis Sci Technol"},{"issue":"8","key":"10.1016\/j.ajo.2025.06.012_bib0041","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/bjophthalmol-2018-312892","article-title":"Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy","volume":"103","author":"Zola","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2025.06.012_bib0042","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","article-title":"Spironolactone for nonresolving Central serous chorioretinopathy: a randomized controlled crossover study","volume":"35","author":"Bousquet","year":"2015","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajo.2025.06.012_bib0043","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"issue":"13","key":"10.1016\/j.ajo.2025.06.012_bib0044","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1111\/bph.15719","article-title":"Approaches towards tissue-selective pharmacology of the mineralocorticoid receptor","volume":"179","author":"Clarisse","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.ajo.2025.06.012_bib0045","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1751-7176.2011.00495.x","article-title":"Spironolactone is more effective than eplerenone at lowering blood pressure in patients with primary aldosteronism","volume":"13","author":"Bloch","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ajo.2025.06.012_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.07.003","article-title":"Central serous chorioretinopathy: towards an evidence-based treatment guideline","volume":"73","author":"van Rijssen","year":"2019","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"10.1016\/j.ajo.2025.06.012_bib0047","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40942-023-00500-w","article-title":"Real-world practice patterns of eplerenone use for central serous chorioretinopathy","volume":"9","author":"Venkatesh","year":"2023","journal-title":"Int J Retina Vitr"},{"issue":"8","key":"10.1016\/j.ajo.2025.06.012_bib0048","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/eye.2014.134","article-title":"Photodynamic therapy for central serous chorioretinopathy","volume":"28","author":"Erikitola","year":"2014","journal-title":"Eye (L)"},{"issue":"7","key":"10.1016\/j.ajo.2025.06.012_bib0049","doi-asserted-by":"crossref","first-page":"e1522","DOI":"10.1111\/aos.15148","article-title":"Clinical impact of the worldwide shortage of verteporfin (Visudyne\u00ae) on ophthalmic care","volume":"100","author":"Sirks","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2025.06.012_bib0050","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.ophtha.2008.08.026","article-title":"Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage","volume":"115","author":"Chen","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.06.012_bib0051","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2018.09.034","article-title":"Predictive factors of response to mineralocorticoid receptor antagonists in nonresolving Central serous chorioretinopathy","volume":"198","author":"Bousquet","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.06.012_bib0052","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/eye.2017.295","article-title":"Response of central serous chorioretinopathy evaluated by multimodal retinal imaging","volume":"32","author":"Sacconi","year":"2018","journal-title":"Eye (L)"},{"key":"10.1016\/j.ajo.2025.06.012_bib0053","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"issue":"14","key":"10.1016\/j.ajo.2025.06.012_bib0054","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajo.2025.06.012_bib0055","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11906-013-0414-8","article-title":"Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles","volume":"16","author":"Danjuma","year":"2014","journal-title":"Curr Hypertens Rep"},{"issue":"10","key":"10.1016\/j.ajo.2025.06.012_bib0056","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ajo.2025.06.012_bib0057","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ajo.2010.06.025","article-title":"Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments","volume":"150","author":"Giani","year":"2010","journal-title":"Am J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425003010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425003010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T02:47:04Z","timestamp":1757818024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425003010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":57,"alternative-id":["S0002939425003010"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.06.012","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eplerenone and Spironolactone for Chronic Central Serous Chorioretinopathy: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}